Founded in September 2025, Sonomind develops non-invasive ultrasound-based treatments aimed at neuropsychiatric conditions, notably treatment-resistant depression. The company plans to enter clinical studies to generate the evidence required for regulatory approvals and aims for CE marking and FDA clearance by 2029. Financially, Sonomind completed a €3 million seed round in 2025 and followed with a €20 million Series A in 2025 that includes €2 million of debt. Leadership includes cofounder Jérémy Bercoff, a physicist with fifteen years’ experience at SuperSonic Imagine. Sonomind is also exploring addressing the Asian market as part of its international expansion plans.

Total raised

$27M

Funding rounds

3

Latest round

Series A

Latest activity

May 2026